MedTrace Logo

Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients

NCT02492217 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2020-11-03

No results posted yet for this study

Summary

To identify new candidate genes and proteins that are differentially expressed in responders' vs non-responders to anti-TNF alpha therapy at the several time points the investigators will use the transcriptomic and proteomic analyses. Demonstrate a link between gene expression and protein markers regarding prediction to anti-TNF alpha therapy efficacy.

Conditions

Interventions

DRUG

Adalimumab

Sponsors & Collaborators

  • Universidade Nova de Lisboa

    lead OTHER

Principal Investigators

  • Fernando M. Pimentel-Santos, MD, PhD · NOVA Medical School/Faculdade de Ciências Médicas

  • Jaime C. Branco, MD, PhD · NOVA Medical School/Faculdade de Ciências Médicas

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2018-05-31
Completion
2018-05-28

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02492217 on ClinicalTrials.gov